Search results
Results from the WOW.Com Content Network
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, [8] which is used in the treatment of schizophrenia, bipolar mania, [9] bipolar depression, [10] and major depressive disorder. [6] It acts primarily as a D 3 and D 2 receptor partial agonist, with a preference for the D 3 ...
It's been approved by the U.S. Food and Drug Administration, in low doses, for use as a short-acting anesthetic in humans and animals, and as a nasal spray (esketamine) for treatment-resistant ...
In 2019, the FDA approved a nasal spray called esketamine (brand name: Spravato) that’s derived from a compound similar to ketamine and is purported to have similar therapeutic effects for the ...
Spravato – a rapid-acting antidepressant of the NMDA receptor antagonist class; enantiomer of ketamine; Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD
Ketamine was first synthesized in 1962, derived from phencyclidine in pursuit of a safer anesthetic with fewer hallucinogenic effects. [29] [30] It was approved for use in the United States in 1970. [19] It has been regularly used in veterinary medicine and was extensively used for surgical anesthesia in the Vietnam War. [31]
Currently approved antipsychotic drugs include Vanda Pharmaceuticals' Fanapt, AbbVie's Vraylar and generic drugs such as olanzapine, quetiapine and aripiprazole, among others.
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
The FDA has not approved ketamine products for the treatment of psychiatric disorders. The agency says there is increased risk in compounded ketamine. FDA warns of risks involved with compounded ...